Welcome to our dedicated page for Satellos Bioscience SEC filings (Ticker: MSCLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates regulatory and disclosure documents related to Satellos Bioscience Inc. (MSCLF), a clinical-stage drug development company focused on degenerative muscle diseases. While no U.S. SEC filings are listed here for the company, investors can use this section alongside other public disclosures to understand how Satellos describes its programs and risks.
Satellos’ communications emphasize the development of SAT-3247, a proprietary, orally administered small molecule drug designed to address deficits in muscle repair and regeneration in Duchenne muscular dystrophy and other degenerative or injury conditions. The company describes SAT-3247 as targeting AAK1 to replace the signal normally provided by dystrophin in muscle stem cells, with the goal of restoring natural muscle repair and regeneration. Its press releases also contain forward-looking information statements and references to risk factors summarized in its Annual Information Form filed on SEDAR+.
On Stock Titan, filing-related pages are designed to complement such disclosures by providing structured access to regulatory documents when available and AI-powered tools to help interpret them. When SEC filings such as annual reports (Form 10-K equivalents for cross-listed issuers), quarterly reports (10-Q), current reports (8-K), registration statements, or insider transaction reports (Form 4) are present, AI-generated summaries can highlight key topics such as clinical development updates, risk discussions, financing activities, and governance information.
For Satellos, users can combine insights from this filings page with the company’s news releases about its Phase 1a/b studies, the LT-001 long-term follow-up trial, and global Phase 2 plans in Duchenne to build a more complete picture of its disclosed development strategy and risk profile.
Satellos Bioscience Inc. is highlighting progress in its lead drug candidate SAT-3247 through two oral presentations and three posters at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 8–11. The talks will cover data from a completed Phase 1a/b study of SAT-3247 in healthy volunteers and adults with Duchenne muscular dystrophy, plus new preclinical data in a mouse model of facioscapulohumeral muscular dystrophy. SAT-3247 is an oral small molecule that targets AAK1, aiming to restore muscle stem cell signaling and promote muscle regeneration as a potential disease-modifying treatment for DMD and other degenerative muscle conditions.
Satellos Bioscience Inc., a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, will present at several upcoming investor conferences. Management is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the TD Cowen 46th Annual Health Care Conference, and the Leerink Partners Global Healthcare Conference, through presentations and investor meetings. Live webcasts of the presentations will be accessible on the company’s website in the Investors section. The company highlights its lead oral small molecule candidate SAT-3247, which targets AAK1 and is being developed as a potential disease-modifying treatment for Duchenne muscular dystrophy, supported by ongoing Phase 2 studies in adult and pediatric participants.
Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.
The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on February 12, 2026, at 10 a.m. ET.
The session will be available via live webcast on Satellos’ investor relations website, with a replay offered afterward. Company leaders will also hold one-on-one meetings with investors. Satellos highlights its lead oral small-molecule candidate SAT-3247, which targets AAK1 and is in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy.
Satellos Bioscience Inc. completed an underwritten public offering in Canada and the United States, raising approximately US$57.2 million in gross proceeds. The financing included 5,168,019 common shares, which reflects the underwriters’ full exercise of their option to purchase an additional 712,574 common shares.
Certain investors received pre-funded warrants to purchase 495,049 common shares instead of shares. Common shares were priced at US$10.10 (C$13.81) each and pre-funded warrants at US$10.09999 (C$13.80999). Satellos plans to use the net proceeds mainly for research and development, including advancing its lead candidate SAT-3247 through clinical trials, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. is launching a primary underwritten offering of common shares and pre-funded warrants in Canada and the United States under a Form F-10 and MJDS structure. The deal includes an over-allotment option for additional common shares and will deliver net proceeds to the company after underwriting commissions and expenses.
The offered shares and warrant shares are being qualified for listing on the Toronto Stock Exchange, and Satellos has also applied to list its common shares on Nasdaq under the symbol “MSLE”. Proceeds are intended to support development of SAT-3247 for Duchenne muscular dystrophy, including the BASECAMP Phase 2 pediatric study and the TRAILHEAD long-term DMD study, and to advance a planned Phase 2 trial in facioscapulohumeral muscular dystrophy. The filing highlights extensive forward-looking risks, potential PFIC tax status for U.S. investors, and the absence of a trading market for the pre-funded warrants, underscoring the speculative nature of this investment.